Gynica, a clinical-stage biotech startup focused on women’s health, has announced the initiation of a first-in-human Phase 1 clinical trial for a novel Endometriosis treatment. Led by renowned expert Prof. Felice Petraglia, the study aims to evaluate Gynica’s non-hormonal, intra-vaginal drug candidates using the IntraVag intra-vaginal drug delivery platform. Endometriosis, affecting over 200 million women worldwide, is characterized by the abnormal growth…
A pioneering drug trial has commenced at a UK hospital, marking a significant milestone in the quest for innovative endometriosis treatments. This Phase II research study, led by the Gynaecology and Research and Development team at NNUH, is examining the safety and effectiveness of a novel antibody, AMY109, developed by Chugai Pharmaceutical Co Ltd. Aimed at reversing the debilitating symptoms of endometriosis…
Serac Healthcare, a clinical radiopharmaceutical company, has made a significant stride in the diagnosis of endometriosis. The company has announced the preliminary results from the first patient cohort in the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) study, focusing on the imaging of endometriosis using the innovative agent 99mTc-maraciclatide. These findings are set to be presented at the Society for Reproductive Investigation…
Pearsanta, a subsidiary of Aditxt, has recently acquired the Mitomic testing platform from MDNA Life Sciences. The transaction, valued at approximately $25 million, is a strategic expansion for Pearsanta, enhancing its capabilities in early disease and cancer detection, particularly in women’s health, focusing on conditions such as endometriosis and ovarian cancer. The Mitomic technology utilizes mitochondrial DNA (mtDNA) to detect diseases at…
In a stride towards non-surgical endometriosis diagnosis, Hera Biotech has announced its impending acquisition of endometriosis diagnostic assets from Scailyte, a company active in single-cell and AI-driven biomarker discovery. This acquisition marks a notable consolidation in the tissue-based diagnostic landscape for endometriosis, a prevalent condition contributing to a significant portion of female infertility and characterized by severe pain due to the abnormal…
Endometriosis, a debilitating disease affecting nearly 190 million women globally, has long been under-recognized and inadequately treated. The need for innovation in the field is evident, and a recent initiative from BioInnovation Institute (BII)‘s Bio Studio program might be a breakthrough. The CurE-me project, under the leadership of Professor Hugo Vankelecom from KU Leuven, seeks to unearth new therapeutic drugs to tackle…
Health Canada has granted approval to MYFEMBREE for the management of pain related to endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The drug, a joint venture between Sumitomo Pharma Canada and Pfizer Canada, is an oral combination therapy meant to be taken once daily. Endometriosis and uterine fibroids are serious health issues affecting a significant portion of…
In an advancement that could change the landscape of endometriosis treatment, pharmaceutical giants Gedeon Richter and Sumitomo Pharma recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for RYEQO. The drug, initially approved for the treatment of uterine fibroids, is on track to receive European Commission (EC) approval for the…
